









Markets
/
Stocks
/
nasdaq-inkt
/

Mink Therapeutics Inc

INKT

13.070USD

+0.260+2.03%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

52.15MMarket Cap

LossP/E TTM



Mink Therapeutics Inc

13.070

+0.260+2.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mink Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mink Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

263 / 501

Overall Ranking

474 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

39.000

Target Price

+204.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mink Therapeutics Inc Highlights

StrengthsRisks

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Undervalued

The company’s latest PE is -0.51, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 61.92K shares, decreasing 43.11% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 23.74K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.60.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Mink Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.10, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.51, which is -62.17% below the recent high of -0.19 and -341.30% above the recent low of -2.25.

Score

Industry at a Glance

Previous score

6.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 263/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Mink Therapeutics Inc is 39.00, with a high of 43.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

39.000

Target Price

+204.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Mink Therapeutics Inc

INKT

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.40, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 15.85 and the support level at 13.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.10

Change

-0.7

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.292

Sell

RSI(14)

40.420

Neutral

STOCH(KDJ)(9,3,3)

12.194

Oversold

ATR(14)

0.796

High Vlolatility

CCI(14)

-146.200

Sell

Williams %R

85.393

Oversold

TRIX(12,20)

-0.247

Sell

StochRSI(14)

30.183

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

13.444

Sell

MA10

13.910

Sell

MA20

14.140

Sell

MA50

14.481

Sell

MA100

14.719

Sell

MA200

11.473

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 1.37%, representing a quarter-over-quarter decrease of 98.20%. The largest institutional shareholder is The Vanguard, holding a total of 23.74K shares, representing 0.53% of shares outstanding, with 11.15% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Agenus, Inc.

2.18M

GKCC, LLC

464.00K

Armen (Garo H.)

172.80K

-0.00%

Corvese (Brian J)

43.97K

+3.02%

Wiinberg Ulf

43.16K

+2.40%

Buell (Jennifer)

36.49K

+54.54%

The Vanguard Group, Inc.

Star Investors

23.74K

Ryan (Barbara A.)

16.77K

+8.27%

Longbow Finance SA

16.67K

Behner (Peter)

14.70K

+8.67%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.